Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
卵巢癌ARID1A突变的机制基础及治疗策略
基本信息
- 批准号:9034830
- 负责人:
- 金额:$ 43.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffectBiochemicalCause of DeathChromatin Remodeling FactorChromatin StructureClinicalDataDevelopmentDiagnosisDiseaseEZH2 geneEpigenetic ProcessEpithelial ovarian cancerFutureGene ExpressionGene TargetingGenesGeneticGoalsHDAC2 geneHumanInterventionKnowledgeLeadMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of ovaryMethodsMissionModelingMolecularMutateMutationMyosin ATPaseOvarian Clear Cell TumorPI3K/AKTPIK3CA genePatientsPlayPrimary NeoplasmProteinsPublic HealthResearchRoleSWI/SNF Family ComplexSeriesSignal TransductionStagingTP53 geneTherapeuticTumor Suppressor ProteinsUnited StatesXenograft procedureactionable mutationbasecancer subtypescancer typechromatin remodelingeffective therapygenome-wideinnovationinsightmouse modelnovel strategiesnovel therapeutic interventionnovel therapeuticsoutcome forecastprototypepublic health relevanceresearch studytargeted treatment
项目摘要
DESCRIPTION (provided by applicant): Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in the United States. Among all EOC subtypes, ovarian clear cell carcinoma (OCCC) carries the worst prognosis when diagnosed at an advanced stage and there is currently no effective therapy for this disease. ARID1A, a subunit of the epigenetic SWI/SNF chromatin remodeler, is among the genes that show the highest mutation rates across many cancer types. In fact, the ARID1A gene is the highest mutated gene in OCCC that occurs in over 50% of the cases. The ultimate goal of the current proposal is to develop novel approaches to treat and eradicate this devastating disease. Since ARID1A is the highest mutated gene in OCCC, we performed an unbiased screen and demonstrated that in ARID1A mutated OCCC the inhibition of EZH2, another epigenetic regulator, is synthetically lethal. The observed synthetic lethality is due to antagonistic roles played by ARID1A and EZH2 in regulating the expression of the same set of target genes. Inhibition of PI3K/AKT signaling contributes to the observed synthetic lethality. Interestingly, ARID1A mutation typically co-exists
with PIK3CA mutation in OCCC. In addition to EZH2, our unexplored data suggest that ARID1A-mutated OCCC cells are also selectively sensitive to inhibition of HDAC2. ARID1A mutation is mutually exclusive from TP53 mutation, and expression of p53 target genes is impaired by ARID1A mutation. However, the mechanism by which ARID1A regulates p53 activity has never been explored. Our preliminary data indicate that ARID1A mutation correlates with the association of myosin IIa (MyoIIa) with the SWI/SNF complex in an ARID1A status-dependent manner. MyoIIa is a known tumor suppressor that is necessary for p53 activity. Thus, these studies suggest that ARID1A mutation impairs p53 activity through MyoIIa sequestration. Our central hypothesis is that ARID1A-mutated OCCC can be treated and ultimately eradicated by targeting the four proteins (namely EZH2, HDAC2, PI3K and p53) we have implicated. Accordingly, three specific aims are proposed: Aim 1: To investigate the role of HDAC2 in the observed synthetic lethality and gene expression antagonism between ARID1A and EZH2; Aim 2. To investigate the mechanisms by which ARID1A regulates p53 activity through MyoIIa; and Aim 3. To develop novel therapeutic strategies for ARID1A mutation. The proposed studies are highly innovative because they challenge current research/clinical paradigms, contribute to new concepts for epigenetic therapeutics, and utilize innovative methods to explore new intervention strategies for ARID1A-mutated OCCC. The research proposed is of high impact because it has the potential to establish the first effective targeted therapeutic strategy for OCCC. Since genetic alterations in components of the SWI/SNF chromatin-remodeling complex occur in more than 20% of all human cancers, the mechanistic insights gained from the current studies will have broad implications for many different types of cancers as well.
描述(由申请人提供):上皮性卵巢癌(EOC)是美国妇科恶性肿瘤中的主要死亡原因。在所有EOC亚型中,卵巢透明细胞癌(OCCC)在晚期诊断时预后最差,目前尚无有效的治疗方法。ARID 1A是表观遗传SWI/SNF染色质重塑子的亚基,是在许多癌症类型中显示出最高突变率的基因之一。事实上,ARID 1A基因是OCCC中突变最高的基因,发生在超过50%的病例中。目前提案的最终目标是开发治疗和根除这种毁灭性疾病的新方法。由于ARID 1A是OCCC中最高突变的基因,我们进行了无偏筛选,并证明在ARID 1A突变的OCCC中,另一种表观遗传调节因子EZH 2的抑制是合成致死的。观察到的合成致死性是由于ARID 1A和EZH 2在调节同一组靶基因的表达中发挥的拮抗作用。PI 3 K/AKT信号传导的抑制有助于观察到的合成致死性。有趣的是,ARID 1A突变通常与
PIK 3CA基因突变。除了EZH 2,我们未探索的数据表明,ARID 1A突变的OCCC细胞也对HDAC 2的抑制选择性敏感。ARID 1A突变与TP 53突变是互斥的,并且ARID 1A突变损害p53靶基因的表达。然而,ARID 1A调节p53活性的机制从未被探索过。我们的初步数据表明,ARID 1A突变与肌球蛋白IIa(MyoIIa)与SWI/SNF复合物以ARID 1A状态依赖性方式相关。MyoIIa是一种已知的肿瘤抑制因子,是p53活性所必需的。因此,这些研究表明,ARID 1A突变通过MyoIIa隔离损害p53活性。我们的中心假设是,ARID 1A突变的OCCC可以通过靶向我们所涉及的四种蛋白质(即EZH 2,HDAC 2,PI 3 K和p53)来治疗并最终根除。因此,提出了三个具体目标:目标1:研究HDAC 2在观察到的ARID 1A和EZH 2之间的合成致死性和基因表达拮抗作用中的作用;目标2。研究ARID 1A通过MyoIIa和Aim 3调节p53活性的机制。为ARID 1A突变的治疗提供新的策略。拟议的研究具有高度创新性,因为它们挑战了当前的研究/临床范式,为表观遗传疗法提供了新的概念,并利用创新方法探索ARID 1A突变OCCC的新干预策略。这项研究具有很高的影响力,因为它有可能为OCCC建立第一个有效的靶向治疗策略。由于SWI/SNF染色质重塑复合物组分的遗传改变发生在超过20%的人类癌症中,因此从目前研究中获得的机制见解也将对许多不同类型的癌症产生广泛的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rugang Zhang其他文献
Rugang Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rugang Zhang', 18)}}的其他基金
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
衰老相关分泌表型的信号基础及其在上皮性卵巢癌中的意义
- 批准号:
10731600 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Metabolic basis of ARID1A-mutated ovarian cancer
ARID1A 突变卵巢癌的代谢基础
- 批准号:
10816829 - 财政年份:2022
- 资助金额:
$ 43.46万 - 项目类别:
Metabolic basis of ARID1A-mutated ovarian cancer
ARID1A 突变卵巢癌的代谢基础
- 批准号:
10378985 - 财政年份:2022
- 资助金额:
$ 43.46万 - 项目类别:
Regulation of tumor recurrence by stress activated neutrophils
应激激活中性粒细胞调节肿瘤复发
- 批准号:
10416030 - 财政年份:2020
- 资助金额:
$ 43.46万 - 项目类别:
Regulation of tumor recurrence by stress activated neutrophils
应激激活中性粒细胞调节肿瘤复发
- 批准号:
10875868 - 财政年份:2020
- 资助金额:
$ 43.46万 - 项目类别:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
基于合成致死率的卵巢癌 ARID1A 突变组合方法
- 批准号:
9980335 - 财政年份:2019
- 资助金额:
$ 43.46万 - 项目类别:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
基于合成致死率的卵巢癌 ARID1A 突变组合方法
- 批准号:
10816361 - 财政年份:2019
- 资助金额:
$ 43.46万 - 项目类别:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
基于合成致死率的卵巢癌 ARID1A 突变组合方法
- 批准号:
10192683 - 财政年份:2019
- 资助金额:
$ 43.46万 - 项目类别:
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
基于合成致死率的卵巢癌 ARID1A 突变组合方法
- 批准号:
10443547 - 财政年份:2019
- 资助金额:
$ 43.46万 - 项目类别:
Overcoming platinum resistance in ovarian cancer through BET inhibition.
通过 BET 抑制克服卵巢癌的铂耐药性。
- 批准号:
10222606 - 财政年份:2018
- 资助金额:
$ 43.46万 - 项目类别:
相似海外基金
CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
- 批准号:
2339759 - 财政年份:2024
- 资助金额:
$ 43.46万 - 项目类别:
Continuing Grant
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
- 批准号:
479334 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Operating Grants
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
- 批准号:
23H02481 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
- 批准号:
2320160 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Standard Grant
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
- 批准号:
10604822 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
- 批准号:
10716621 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
- 批准号:
10655891 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
- 批准号:
10621634 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Examination of risk assessment and biochemical assessment of fracture development focusing on the body composition of patients with rheumatoid arthritis
关注类风湿性关节炎患者身体成分的骨折发生风险评估和生化评估检查
- 批准号:
22KJ2600 - 财政年份:2023
- 资助金额:
$ 43.46万 - 项目类别:
Grant-in-Aid for JSPS Fellows